Article
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Aug 2010
Lugthart Sanne, Gröschel Stefan, Beverloo H Berna, Kayser Sabine, Valk Peter J M, van Zelderen-Bhola Shama Lydia, Jan Ossenkoppele Gert, Vellenga Edo, van den Berg-de Ruiter Eva, Schanz Urs, Verhoef Gregor, Vandenberghe Peter, Ferrant Augustin, Köhne Claus-Henning, Pfreundschuh Michael, Horst Heinz A, Koller Elisabeth, von Lilienfeld-Toal Marie, Bentz Martin, Ganser Arnold, Schlegelberger Brigitte, Jotterand Martine, Krauter Jürgen, Pabst Thomas, Theobald Matthias, Schlenk Richard F, Delwel Ruud, Döhner Konstanze, Löwenberg Bob, Döhner Hartmut
Abstract excerpt
PURPOSE: Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved. PATIENTS AND METHODS: Cytogenetics, molecular genetics, therapy response, and outcome analysis were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.